ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials

Dearden, 2013, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap), Ann Oncol, 24, 2371, 10.1093/annonc/mdt205 Barlesi, 2016, Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients with previously treated ALK+ non–small-cell lung cancer (NSCLC), Ann Oncol, 27 Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non–small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X Ou, 2020, Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non–small-cell lung cancer, Lung Cancer, 139, 22, 10.1016/j.lungcan.2019.10.015 Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795 Camidge, 2019, Updated efficacy and safety data and impact of EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non–small cell lung cancer in the global phase III ALEX study, J Thorac Oncol, 14, 1233, 10.1016/j.jtho.2019.03.007 Gainor, 2016, Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer, Cancer Discov, 6, 1118, 10.1158/2159-8290.CD-16-0596 Dong, 2016, Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non–small cell lung cancer cells, Neoplasia, 18, 162, 10.1016/j.neo.2016.02.001 Bayliss, 2016, Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs, Cell Mol Life Sci, 73, 1209, 10.1007/s00018-015-2117-6 Lin, 2017, Targeting ALK: precision medicine takes on drug resistance, Cancer Discov, 7, 137, 10.1158/2159-8290.CD-16-1123 Ou, 2016, ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression, Lung Cancer, 91, 70, 10.1016/j.lungcan.2015.09.006 Newman, 2014, An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, 20, 548, 10.1038/nm.3519 Newman, 2016, Integrated digital error suppression for improved detection of circulating tumor DNA, Nat Biotechnol, 34, 547, 10.1038/nbt.3520 Bamford, 2004, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br J Cancer, 91, 355, 10.1038/sj.bjc.6601894 Puig, 2016, Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non–small-cell lung cancer (NSCLC), J Clin Oncol, 34, abstr 9061, 10.1200/JCO.2016.34.15_suppl.9061 Noh, 2017, Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non–small cell lung cancer (NSCLC), J Pathol, 243, 307, 10.1002/path.4950 Katayama, 2014, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib, Cancer Res, 20, 5686 Soo, 2011, Ethnic differences in survival outcome in patients with advanced stage non–small cell lung cancer: results of a meta-analysis of randomized controlled trials, J Thorac Oncol, 6, 1030, 10.1097/JTO.0b013e3182199c03 Gainor, 2015, Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib, Clin Cancer Res, 21, 2745, 10.1158/1078-0432.CCR-14-3009 Cao, 2018, The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non–small cell lung cancer patients, Onco Targets Ther, 11, 2637, 10.2147/OTT.S155995 Klega, 2018, Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors, JCO Precis Oncol, 10.1200/PO.17.00285 Dawson, 2013, Analysis of circulating tumor DNA to monitor metastatic breast cancer, N Engl J Med, 368, 1199, 10.1056/NEJMoa1213261 Gadgeel, 2018, Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non–small-cell lung cancer: CNS efficacy results from the ALEX study, Ann Oncol, 29, 2214, 10.1093/annonc/mdy405 Chuang, 2019, Molecular modeling of ALK L1198F and/or G1202R mutations to determine differential crizotinib sensitivity, Sci Rep, 9, 11390, 10.1038/s41598-019-46825-1 Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, 4, 120ra17, 10.1126/scitranslmed.3003316 Dagogo-Jack, 2019, Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity, Clin Cancer Res, 25, 6662, 10.1158/1078-0432.CCR-19-1436 Shaw, 2019, ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancer, J Clin Oncol, 37, 1370, 10.1200/JCO.18.02236